SpringWorks TherapeuticsSWTX
SWTX
About: SpringWorks Therapeutics Inc is a clinical stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers.
Employees: 305
0
Funds holding %
of 6,823 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
70% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 23
45% more repeat investments, than reductions
Existing positions increased: 87 | Existing positions reduced: 60
6% more funds holding
Funds holding: 207 [Q2] → 220 (+13) [Q3]
0.96% more ownership
Funds ownership: 107.71% [Q2] → 108.66% (+0.96%) [Q3]
14% less capital invested
Capital invested by funds: $3.01B [Q2] → $2.59B (-$420M) [Q3]
33% less funds holding in top 10
Funds holding in top 10: 6 [Q2] → 4 (-2) [Q3]
51% less call options, than puts
Call options by funds: $4.46M | Put options by funds: $9.02M
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$60
73%
upside
Avg. target
$71
104%
upside
High target
$78
125%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Guggenheim Michael Schmidt 30% 1-year accuracy 6 / 20 met price target | 125%upside $78 | Buy Maintained | 8 Jan 2025 |
Evercore ISI Group Cory Kasimov 40% 1-year accuracy 6 / 15 met price target | 73%upside $60 | Outperform Initiated | 20 Nov 2024 |
HC Wainwright & Co. Robert Burns 24% 1-year accuracy 38 / 160 met price target | 114%upside $74 | Buy Maintained | 12 Nov 2024 |
Financial journalist opinion
Based on 6 articles about SWTX published over the past 30 days
Negative
Zacks Investment Research
6 days ago
SWTX Announces 2024 Preliminary Results, 2025 Goals, Stock Down
SpringWorks reports preliminary fourth-quarter and full-year 2024 product revenues. It also provides updates across the commercial portfolio and other pipelines.
Neutral
GlobeNewsWire
1 week ago
SpringWorks Therapeutics Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates at 43rd Annual J.P. Morgan Healthcare Conference
– Achieved $61.5 million and $172.0 million in preliminary fourth quarter and full year 2024 OGSIVEO ® (nirogacestat) U.S. net product revenues, respectively –
Positive
Seeking Alpha
1 week ago
SpringWorks: PDUFA Review Date Could Lead To Next Approved Pipeline Candidate
SpringWorks has shown strong revenue growth with OGSIVEO, achieving a 23% increase from Q2 of 2024 to Q3 of 2024, and potential EMA approval if it could boost sales further. Mirdametinib, a MEK inhibitor for NF1-PN, has a PDUFA date of February 28th of 2025, and could unlock significant shareholder value if approved. Results from phase 1b study using brimarafenib to treat patients with MAPK mutant solid tumors are expected to be released in the 2nd half of 2025.
Positive
Zacks Investment Research
1 week ago
Strength Seen in SpringWorks Therapeutics (SWTX): Can Its 6.0% Jump Turn into More Strength?
SpringWorks Therapeutics (SWTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Neutral
GlobeNewsWire
2 weeks ago
SpringWorks Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
STAMFORD, Conn., Jan. 03, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that Saqib Islam, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 11:15 a.m. PT.
Positive
Seeking Alpha
2 weeks ago
SpringWorks: With Catalyst On The Horizon And Growing Sales, 2025 Looks Great
SpringWorks Therapeutics shows promising growth with their first approved drug and an imminent second approval for mirdametinib in NF1 treatment. SWTX's financials reveal strong cash reserves and growing sales, though they remain unprofitable, with a net loss of $53.5 million in Q3 2024. Strengths include sustained sales growth and potential back-to-back drug approvals, but risks involve market competition and aggressive goal setting.
Positive
Seeking Alpha
1 month ago
Tarsus Pharmaceuticals & SpringWorks Therapeutics: Jonathan Faison's Top 2 Picks
Jonathan Faison runs the ROTY Biotech Community. Why he's high on Tarsus Pharmaceuticals and his #1 holding, SpringWorks Therapeutics.
Positive
Zacks Investment Research
1 month ago
SpringWorks Therapeutics (SWTX) Up 14.5% Since Last Earnings Report: Can It Continue?
SpringWorks Therapeutics (SWTX) reported earnings 30 days ago. What's next for the stock?
Neutral
GlobeNewsWire
1 month ago
SpringWorks Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference
STAMFORD, Conn., Nov. 26, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that management will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference, taking place in Coral Gables, Florida on Tuesday, December 3, 2024 at 12:30 p.m. ET.
Positive
Zacks Investment Research
2 months ago
Does SpringWorks Therapeutics (SWTX) Have the Potential to Rally 92.68% as Wall Street Analysts Expect?
The mean of analysts' price targets for SpringWorks Therapeutics (SWTX) points to a 92.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Charts implemented using Lightweight Charts™